These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 23369185)

  • 1. Naphthalimide derivatives with therapeutic characteristics: a patent review.
    Kamal A; Bolla NR; Srikanth PS; Srivastava AK
    Expert Opin Ther Pat; 2013 Mar; 23(3):299-317. PubMed ID: 23369185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acridine derivatives: a patent review (2009 - 2010).
    Kaur J; Singh P
    Expert Opin Ther Pat; 2011 Apr; 21(4):437-54. PubMed ID: 21323399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,8-Naphthalimide: A Potent DNA Intercalator and Target for Cancer Therapy.
    Tandon R; Luxami V; Kaur H; Tandon N; Paul K
    Chem Rec; 2017 Oct; 17(10):956-993. PubMed ID: 28375569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel naphthalimide-amino acid conjugates with flexible leucine moiety as side chain: design, synthesis and potential antitumor activity.
    Wu A; Xu Y; Qian X
    Bioorg Med Chem; 2009 Jan; 17(2):592-9. PubMed ID: 19109022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the development of 1,8-naphthalimide based DNA targeting binders, anticancer and fluorescent cellular imaging agents.
    Banerjee S; Veale EB; Phelan CM; Murphy SA; Tocci GM; Gillespie LJ; Frimannsson DO; Kelly JM; Gunnlaugsson T
    Chem Soc Rev; 2013 Feb; 42(4):1601-18. PubMed ID: 23325367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterocyclic Naphthalimides as New Skeleton Structure of Compounds with Increasingly Expanding Relational Medicinal Applications.
    Gong HH; Addla D; Lv JS; Zhou CH
    Curr Top Med Chem; 2016; 16(28):3303-3364. PubMed ID: 27150364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Non-amino aromatic substituted naphthalimides as potential antitumor agents: Synthesis via Suzuki reaction, antiproliferative activity, and DNA-binding behavior.
    Xie L; Cui J; Qian X; Xu Y; Liu J; Xu R
    Bioorg Med Chem; 2011 Jan; 19(2):961-7. PubMed ID: 21208805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular design, chemical synthesis, and biological evaluation of '4-1' pentacyclic aryl/heteroaryl-imidazonaphthalimides.
    Li F; Cui J; Guo L; Qian X; Ren W; Wang K; Liu F
    Bioorg Med Chem; 2007 Aug; 15(15):5114-21. PubMed ID: 17532640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naphthalimide intercalators with chiral amino side chains: effects of chirality on DNA binding, photodamage and antitumor cytotoxicity.
    Yang Q; Yang P; Qian X; Tong L
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6210-3. PubMed ID: 18930399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescent organometallic rhodium(I) and ruthenium(II) metallodrugs with 4-ethylthio-1,8-naphthalimide ligands: Antiproliferative effects, cellular uptake and DNA-interaction.
    Streciwilk W; Terenzi A; Cheng X; Hager L; Dabiri Y; Prochnow P; Bandow JE; Wölfl S; Keppler BK; Ott I
    Eur J Med Chem; 2018 Aug; 156():148-161. PubMed ID: 30006161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remarkable DNA binding affinity and potential anticancer activity of pyrrolo[2,1-c][1,4]benzodiazepine-naphthalimide conjugates linked through piperazine side-armed alkane spacers.
    Kamal A; Ramu R; Tekumalla V; Khanna GB; Barkume MS; Juvekar AS; Zingde SM
    Bioorg Med Chem; 2008 Aug; 16(15):7218-24. PubMed ID: 18656370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naphthalimides and azonafides as promising anti-cancer agents.
    Ingrassia L; Lefranc F; Kiss R; Mijatovic T
    Curr Med Chem; 2009; 16(10):1192-213. PubMed ID: 19355879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. l,8-Naphthalimide based DNA intercalators and anticancer agents. A systematic review from 2007 to 2017.
    Tomczyk MD; Walczak KZ
    Eur J Med Chem; 2018 Nov; 159():393-422. PubMed ID: 30312931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel anti-tumor agents of 4-triazol-1,8-naphthalimides: synthesis, cytotoxicity, DNA intercalation and photocleavage.
    Li X; Lin Y; Wang Q; Yuan Y; Zhang H; Qian X
    Eur J Med Chem; 2011 Apr; 46(4):1274-9. PubMed ID: 21345546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A fruitful decade from 2005 to 2014 for anthraquinone patents.
    Hussain H; Al-Harrasi A; Al-Rawahi A; Green IR; Csuk R; Ahmed I; Shah A; Abbas G; Rehman NU; Ullah R
    Expert Opin Ther Pat; 2015; 25(9):1053-64. PubMed ID: 26036306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel naphthalimide derivatives as potential apoptosis-inducing agents: design, synthesis and biological evaluation.
    Wu A; Xu Y; Qian X; Wang J; Liu J
    Eur J Med Chem; 2009 Nov; 44(11):4674-80. PubMed ID: 19643513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxo-heterocyclic fused naphthalimides as antitumor agents: synthesis and biological evaluation.
    Tan S; Yin H; Chen Z; Qian X; Xu Y
    Eur J Med Chem; 2013 Apr; 62():130-8. PubMed ID: 23353750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel naphthalimide-benzoic acid conjugates as potential apoptosis-inducing agents: design, synthesis, and biological activity.
    Wu A; Mei P; Xu Y; Qian X
    Chem Biol Drug Des; 2011 Dec; 78(6):941-7. PubMed ID: 21958160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Overview of Naphthylimide as Specific Scaffold for New Drug Discovery.
    Ruan W; Xie Z; Wang Y; Xia L; Guo Y; Qiao D
    Molecules; 2024 Sep; 29(19):. PubMed ID: 39407459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gold(I) N-heterocyclic carbene complexes with naphthalimide ligands as combined thioredoxin reductase inhibitors and DNA intercalators.
    Meyer A; Oehninger L; Geldmacher Y; Alborzinia H; Wölfl S; Sheldrick WS; Ott I
    ChemMedChem; 2014 Aug; 9(8):1794-800. PubMed ID: 24803348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.